FAM13A affects body fat distribution and adipocyte function.

Adipocytes / metabolism Adipogenesis / genetics Animals Body Fat Distribution Cell Differentiation / genetics GTPase-Activating Proteins / genetics Gene Knockdown Techniques Genetic Loci Genome-Wide Association Study HEK293 Cells Humans Insulin Resistance / genetics Intra-Abdominal Fat / metabolism Male Metabolomics Mice, Inbred C57BL Mice, Knockout Phenotype Polymorphism, Single Nucleotide / genetics RNA, Messenger / genetics Subcutaneous Fat / metabolism

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
19 03 2020
Historique:
received: 30 10 2018
accepted: 20 02 2020
entrez: 21 3 2020
pubmed: 21 3 2020
medline: 16 7 2020
Statut: epublish

Résumé

Genetic variation in the FAM13A (Family with Sequence Similarity 13 Member A) locus has been associated with several glycemic and metabolic traits in genome-wide association studies (GWAS). Here, we demonstrate that in humans, FAM13A alleles are associated with increased FAM13A expression in subcutaneous adipose tissue (SAT) and an insulin resistance-related phenotype (e.g. higher waist-to-hip ratio and fasting insulin levels, but lower body fat). In human adipocyte models, knockdown of FAM13A in preadipocytes accelerates adipocyte differentiation. In mice, Fam13a knockout (KO) have a lower visceral to subcutaneous fat (VAT/SAT) ratio after high-fat diet challenge, in comparison to their wild-type counterparts. Subcutaneous adipocytes in KO mice show a size distribution shift toward an increased number of smaller adipocytes, along with an improved adipogenic potential. Our results indicate that GWAS-associated variants within the FAM13A locus alter adipose FAM13A expression, which in turn, regulates adipocyte differentiation and contribute to changes in body fat distribution.

Identifiants

DOI: 10.1038/s41467-020-15291-z PMID: 32193374 PMC: PMC7081215
pubmed: 32193374
doi: 10.1038/s41467-020-15291-z
pii: 10.1038/s41467-020-15291-z
pmc: PMC7081215
doi:

Substances chimiques

FAM13A protein, human 0
Fam13a protein, mouse 0
GTPase-Activating Proteins 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1465

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK101573
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK106236
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK120565
Pays : United States
Organisme : NLM NIH HHS
ID : T15 LM007033
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK116750
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK116074
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM131810
Pays : United States

Références

Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 518, 187–196 (2015).
pubmed: 25673412 pmcid: 4338562
Loos, R. J. F. & Kilpelainen, T. O. Genes that make you fat, but keep you healthy. J. Intern. Med. 284, 450–463 (2018).
pubmed: 30144199 pmcid: 6566096
Scott, R. A. et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat. Genet. 44, 991–1005 (2012).
pubmed: 22885924 pmcid: 3433394
Lotta, L. A. et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat. Genet. 49, 17–26 (2017).
pubmed: 27841877
Yaghootkar, H. et al. Genetic evidence for a normal-weight “metabolically obese” phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes 63, 4369–4377 (2014).
pubmed: 25048195 pmcid: 4392920
Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274–1283 (2013).
pubmed: 24097068 pmcid: 3838666
Cho, M. H. et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat. Genet. 42, 200–202 (2010).
pubmed: 20173748 pmcid: 2828499
Zhang, Y. et al. High expression of FAM13A was associated with increasing the liver cirrhosis risk. Mol. Genet. Genom. Med. 7, e543 (2019).
Fagerberg, L. et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell Proteomics 13, 397–406 (2014).
pubmed: 24309898
Hormozdiari, F. et al. Colocalization of GWAS and eQTL signals detects target genes. Am. J. Hum. Genet. 99, 1245–1260 (2016).
pubmed: 27866706 pmcid: 5142122
Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).
pubmed: 25826379 pmcid: 4380465
Rao, A. S. et al. Large-scale phenome-wide association study of PCSK9 variants demonstrates protection against ischemic stroke. Circ. Genom. Precis. Med. 11, e002162 (2018).
pubmed: 29997226 pmcid: 6050027
Davis, J. P. et al. Common, low-frequency, and rare genetic variants associated with lipoprotein subclasses and triglyceride measures in Finnish men from the METSIM study. PLoS Genet. 13, e1007079 (2017).
pubmed: 29084231 pmcid: 5679656
Laakso, M. et al. The metabolic syndrome in men study: a resource for studies of metabolic and cardiovascular diseases. J. Lipid Res. 58, 481–493 (2017).
pubmed: 28119442 pmcid: 5335588
Herwig, R., Hardt, C., Lienhard, M. & Kamburov, A. Analyzing and interpreting genome data at the network level with ConsensusPathDB. Nat. Protoc. 11, 1889–1907 (2016).
pubmed: 27606777
Hägg, S. et al. Multi-organ expression profiling uncovers a gene module in coronary artery disease involving transendothelial migration of leukocytes and LIM domain binding 2: the stockholm atherosclerosis gene expression (STAGE) study. PLOS Genet. 5, e1000754 (2009).
pubmed: 19997623 pmcid: 2780352
Wabitsch, M. et al. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J. Obes. Relat. Metab. Disord. 25, 8–15 (2001).
pubmed: 11244452
Small, K. S. et al. Regulatory variants at KLF14 influence type 2 diabetes risk via a female-specific effect on adipocyte size and body composition. Nat. Genet. 50, 572–580 (2018).
pubmed: 29632379 pmcid: 5935235
Civelek, M. et al. Genetic regulation of adipose gene expression and cardio-metabolic traits. Am. J. Hum. Genet. 100, 428–443 (2017).
pubmed: 28257690 pmcid: 5339333
Agarwal, A. K. et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat. Genet. 31, 21–23 (2002).
pubmed: 11967537
Cautivo, K. M. et al. AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. Mol. Metab. 5, 491–505 (2016).
pubmed: 27408775 pmcid: 4921804
Ussar, S. et al. ASC-1, PAT2, and P2RX5 are cell surface markers for white, beige, and brown adipocytes. Sci. Transl. Med. 6, 247ra103 (2014).
pubmed: 25080478 pmcid: 4356008
Cao, Y. Angiogenesis modulates adipogenesis and obesity. J. Clin. Invest. 117, 2362–2368 (2007).
pubmed: 17786229 pmcid: 1963348
Warren, C. R. et al. Induced pluripotent stem cell differentiation enables functional validation of GWAS variants in metabolic disease. Cell Stem Cell 20, 547–557 e547 (2017).
pubmed: 28388431
Fischer, C. et al. A miR-327-FGF10-FGFR2-mediated autocrine signaling mechanism controls white fat browning. Nat. Commun. 8, 2079 (2017).
pubmed: 29233981 pmcid: 5727036
Mardinoglu, A. et al. Extensive weight loss reveals distinct gene expression changes in human subcutaneous and visceral adipose tissue. Sci. Rep. 5, 14841 (2015).
pubmed: 26434764 pmcid: 4593186
Kaess, B. M. et al. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia 55, 2622–2630 (2012).
pubmed: 22898763 pmcid: 3636065
Guilherme, A., Virbasius, J. V., Puri, V. & Czech, M. P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9, 367–377 (2008).
pubmed: 18401346 pmcid: 2886982
Shepherd, P. R. et al. Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J. Biol. Chem. 268, 22243–22246 (1993).
pubmed: 8226728
Kusminski, C. M. et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat. Med. 18, 1539–1549 (2012).
pubmed: 22961109 pmcid: 3745511
Yamauchi, T. et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276, 41245–41254 (2001).
pubmed: 11533050
Rosen, E. D. & Spiegelman, B. M. What we talk about when we talk about fat. Cell 156, 20–44 (2014).
pubmed: 24439368 pmcid: 3934003
Corvol, H., Hodges, C. A., Drumm, M. L. & Guillot, L. Moving beyond genetics: is FAM13A a major biological contributor in lung physiology and chronic lung diseases? J. Med. Genet. 51, 646–649 (2014).
pubmed: 25163686
Sordella, R., Jiang, W., Chen, G. C., Curto, M. & Settleman, J. Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell 113, 147–158 (2003).
pubmed: 12705864
Christodoulides, C., Lagathu, C., Sethi, J. K. & Vidal-Puig, A. Adipogenesis and WNT signalling. Trends Endocrinol. Metab. 20, 16–24 (2009).
pubmed: 19008118
Tang, J. et al. Obesity-associated family with sequence similarity 13, member A (FAM13A) is dispensable for adipose development and insulin sensitivity. Int. J. Obes. 43, 1269–1280 (2019).
Wardhana, D. A. et al. Family with sequence similarity 13, member A modulates adipocyte insulin signaling and preserves systemic metabolic homeostasis. Proc. Natl Acad. Sci. USA 115, 1529–1534 (2018).
pubmed: 29386390
Lundback, V. et al. FAM13A and POM121C are candidate genes for fasting insulin: functional follow-up analysis of a genome-wide association study. Diabetologia 61, 1112–1123 (2018).
pubmed: 29487953 pmcid: 6448992
Chusyd, D. E., Wang, D., Huffman, D. M. & Nagy, T. R. Relationships between rodent white adipose fat pads and human white adipose fat depots. Front. Nutr. 3, 10 (2016).
pubmed: 27148535 pmcid: 4835715
Rao, A. S. et al. Large-scale phenome-wide association study of PCSK9 loss-of-function variants demonstrates protection against ischemic stroke. Circ Genom Precis Med. 11, e002162 (2018).
pubmed: 29997226 pmcid: 6050027
Talukdar, H. A. et al. Cross-tissue regulatory gene networks in coronary artery disease. Cell Syst. 2, 196–208 (2016).
pubmed: 27135365 pmcid: 4855300
Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008).
Jin, Z. et al. Regulation of nuclear-cytoplasmic shuttling and function of Family with sequence similarity 13, member A (Fam13a), by B56-containing PP2As and Akt. Mol. Biol. Cell 26, 1160–1173 (2015).
pubmed: 25609086 pmcid: 4357514
Fischer, A. H., Jacobson, K. A., Rose, J. & Zeller, R. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2008, pdb prot4986 (2008).
pubmed: 21356829
Galarraga, M. et al. Adiposoft: automated software for the analysis of white adipose tissue cellularity in histological sections. J. Lipid Res. 53, 2791–2796 (2012).
pubmed: 22993232 pmcid: 3494244
Bourgeois, F., Alexiu, A. & Lemonnier, D. Dietary-induced obesity: effect of dietary fats on adipose tissue cellularity in mice. Br. J. Nutr. 49, 17–26 (1983).
pubmed: 6821685
Knowles, J. W. et al. Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. J. Clin. Invest. 125, 1739–1751 (2015).
pubmed: 25798622 pmcid: 4409020
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 pmcid: 23104886
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
pubmed: 19910308 pmcid: 19910308
Clee, S. M., Nadler, S. T. & Attie, A. D. Genetic and genomic studies of the BTBR ob/ob mouse model of type 2 diabetes. Am. J. Ther. 12, 491–498 (2005).
pubmed: 16280642
Li, J., Daly, E., Campioli, E., Wabitsch, M. & Papadopoulos, V. De novo synthesis of steroids and oxysterols in adipocytes. J. Biol. Chem. 289, 747–764 (2014).
pubmed: 24280213
Fischer-Posovszky, P., Newell, F. S., Wabitsch, M. & Tornqvist, H. E. Human SGBS cells - a unique tool for studies of human fat cell biology. Obes. Facts 1, 184–189 (2008).
pubmed: 20054179 pmcid: 6452113
Horlbeck, M. A. et al. Nucleosomes impede Cas9 access to DNA in vivo and in vitro. Elife 5, e12677 (2016).
pubmed: 26987018 pmcid: 4861601
Gilbert, L. A. et al. Genome-Scale CRISPR-mediated control of gene repression and activation. Cell 159, 647–661 (2014).
pubmed: 25307932 pmcid: 4253859

Auteurs

Mohsen Fathzadeh (M)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.
ORCID: 0000-0002-7962-9148

Jiehan Li (J)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.

Abhiram Rao (A)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Bioengineering Department, School of Engineering and Medicine, Stanford, CA, USA.

Naomi Cook (N)

Department of Medical Sciences, Molecular Epidemiology, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0002-1830-2432

Indumathi Chennamsetty (I)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.

Marcus Seldin (M)

Department of Human Genetics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
ORCID: 0000-0001-8026-4759

Xiang Zhou (X)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.

Panjamaporn Sangwung (P)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.
ORCID: 0000-0002-8145-7947

Michael J Gloudemans (MJ)

Department of Genetics, Stanford University, California, CA, USA.
ORCID: 0000-0002-9924-9943

Mark Keller (M)

Department of Biochemistry, University of Wisconsin, Madison, WI, USA.

Allan Attie (A)

Department of Biochemistry, University of Wisconsin, Madison, WI, USA.
ORCID: 0000-0002-0568-2261

Jing Yang (J)

Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
ORCID: 0000-0002-4983-1660

Martin Wabitsch (M)

Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany.

Ivan Carcamo-Orive (I)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.
ORCID: 0000-0001-8823-4925

Yuko Tada (Y)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
ORCID: 0000-0003-1410-9894

Aldons J Lusis (AJ)

Department of Human Genetics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
ORCID: 0000-0001-9013-0228

Myung Kyun Shin (MK)

Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, NJ, USA.

Cliona M Molony (CM)

Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, NJ, USA.

Tracey McLaughlin (T)

Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.
Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, USA.

Gerald Reaven (G)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.

Stephen B Montgomery (SB)

Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.
Department of Genetics, Stanford University, California, CA, USA.
Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Pathology, Stanford University, California, CA, USA.
ORCID: 0000-0002-5200-3903

Dermot Reilly (D)

Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, NJ, USA.
ORCID: 0000-0002-9456-1364

Thomas Quertermous (T)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.
ORCID: 0000-0002-7645-9067

Erik Ingelsson (E)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. eriking@stanford.edu.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA. eriking@stanford.edu.
Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA. eriking@stanford.edu.
ORCID: 0000-0003-2256-6972

Joshua W Knowles (JW)

Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. knowlej@stanford.edu.
Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA. knowlej@stanford.edu.
Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA. knowlej@stanford.edu.
ORCID: 0000-0003-1922-7240

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Cellules › Cellules du tissu conjonctif › Adipocytes › FAM13A affects body fat distribution and...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Différenciation cellulaire › Adipogenèse › FAM13A affects body fat distribution and...
questionsmedicales.fr › Eucaryotes › Animaux › FAM13A affects body fat distribution and...
questionsmedicales.fr › Phénomènes physiologiques › Constitution physique › Composition corporelle › Répartition du tissu adipeux › FAM13A affects body fat distribution and...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Différenciation cellulaire › FAM13A affects body fat distribution and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Régulateurs des protéines G › Protéines d'activation de la GTPase › FAM13A affects body fat distribution and...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Ciblage de gène › Techniques de knock-down de gènes › FAM13A affects body fat distribution and...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Locus génétiques › FAM13A affects body fat distribution and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Épidémiologie moléculaire › Étude d'association pangénomique › FAM13A affects body fat distribution and...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › FAM13A affects body fat distribution and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › FAM13A affects body fat distribution and...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Insulinorésistance › FAM13A affects body fat distribution and...
questionsmedicales.fr › Tissus › Tissu conjonctif › Tissu adipeux › Tissu adipeux blanc › Graisse abdominale › Graisse intra-abdominale › FAM13A affects body fat distribution and...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Métabolomique › FAM13A affects body fat distribution and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › FAM13A affects body fat distribution and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › FAM13A affects body fat distribution and...
questionsmedicales.fr › Phénomènes génétiques › Phénotype › FAM13A affects body fat distribution and...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Polymorphisme de nucléotide simple › FAM13A affects body fat distribution and...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN messager › FAM13A affects body fat distribution and...
questionsmedicales.fr › Tissus › Tissu conjonctif › Tissu adipeux › Tissu adipeux blanc › Graisse sous-cutanée › FAM13A affects body fat distribution and...